nodes	percent_of_prediction	percent_of_DWPC	metapath
Brompheniramine—CYP2B6—Efavirenz—acquired immunodeficiency syndrome	0.0413	0.0433	CbGbCtD
Brompheniramine—CYP2B6—Nevirapine—acquired immunodeficiency syndrome	0.0388	0.0407	CbGbCtD
Brompheniramine—CYP2B6—Lopinavir—acquired immunodeficiency syndrome	0.0388	0.0407	CbGbCtD
Brompheniramine—CYP2B6—Amprenavir—acquired immunodeficiency syndrome	0.0351	0.0368	CbGbCtD
Brompheniramine—CYP2B6—Nelfinavir—acquired immunodeficiency syndrome	0.0294	0.0309	CbGbCtD
Brompheniramine—CYP2E1—Ritonavir—acquired immunodeficiency syndrome	0.027	0.0283	CbGbCtD
Brompheniramine—CYP2B6—Ritonavir—acquired immunodeficiency syndrome	0.0266	0.0279	CbGbCtD
Brompheniramine—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.0266	0.0279	CbGbCtD
Brompheniramine—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.0266	0.0279	CbGbCtD
Brompheniramine—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.0263	0.0275	CbGbCtD
Brompheniramine—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.0247	0.0259	CbGbCtD
Brompheniramine—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.0223	0.0234	CbGbCtD
Brompheniramine—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.0223	0.0234	CbGbCtD
Brompheniramine—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0218	0.0229	CbGbCtD
Brompheniramine—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0205	0.0215	CbGbCtD
Brompheniramine—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0205	0.0215	CbGbCtD
Brompheniramine—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.0202	0.0211	CbGbCtD
Brompheniramine—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.0202	0.0211	CbGbCtD
Brompheniramine—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.02	0.0209	CbGbCtD
Brompheniramine—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.0193	0.0203	CbGbCtD
Brompheniramine—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.0193	0.0202	CbGbCtD
Brompheniramine—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0188	0.0197	CbGbCtD
Brompheniramine—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0188	0.0197	CbGbCtD
Brompheniramine—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.0187	0.0196	CbGbCtD
Brompheniramine—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0186	0.0195	CbGbCtD
Brompheniramine—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0186	0.0195	CbGbCtD
Brompheniramine—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.017	0.0178	CbGbCtD
Brompheniramine—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.017	0.0178	CbGbCtD
Brompheniramine—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.0169	0.0177	CbGbCtD
Brompheniramine—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.0169	0.0177	CbGbCtD
Brompheniramine—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.0162	0.017	CbGbCtD
Brompheniramine—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.016	0.0168	CbGbCtD
Brompheniramine—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.0156	0.0163	CbGbCtD
Brompheniramine—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0146	0.0154	CbGbCtD
Brompheniramine—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0142	0.0149	CbGbCtD
Brompheniramine—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.0141	0.0148	CbGbCtD
Brompheniramine—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.0141	0.0148	CbGbCtD
Brompheniramine—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.0135	0.0141	CbGbCtD
Brompheniramine—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0129	0.0135	CbGbCtD
Brompheniramine—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0129	0.0135	CbGbCtD
Brompheniramine—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0127	0.0133	CbGbCtD
Brompheniramine—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0119	0.0125	CbGbCtD
Brompheniramine—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0119	0.0125	CbGbCtD
Brompheniramine—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0108	0.0113	CbGbCtD
Brompheniramine—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0108	0.0113	CbGbCtD
Brompheniramine—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00931	0.00977	CbGbCtD
Brompheniramine—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00904	0.00948	CbGbCtD
Brompheniramine—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00818	0.00858	CbGbCtD
Brompheniramine—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00818	0.00858	CbGbCtD
Brompheniramine—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00784	0.00822	CbGbCtD
Brompheniramine—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.00152	0.0385	CbGeAlD
Brompheniramine—CHRM5—skin of body—acquired immunodeficiency syndrome	0.00141	0.0356	CbGeAlD
Brompheniramine—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.00133	0.0336	CbGeAlD
Brompheniramine—CYP2B6—blood plasma—acquired immunodeficiency syndrome	0.00119	0.0301	CbGeAlD
Brompheniramine—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.00118	0.0298	CbGeAlD
Brompheniramine—CYP2E1—blood plasma—acquired immunodeficiency syndrome	0.00112	0.0283	CbGeAlD
Brompheniramine—CHRM4—nervous system—acquired immunodeficiency syndrome	0.00111	0.0282	CbGeAlD
Brompheniramine—CHRM4—central nervous system—acquired immunodeficiency syndrome	0.00107	0.0271	CbGeAlD
Brompheniramine—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000899	0.0227	CbGeAlD
Brompheniramine—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000885	0.0224	CbGeAlD
Brompheniramine—CHRM5—nervous system—acquired immunodeficiency syndrome	0.000871	0.022	CbGeAlD
Brompheniramine—CHRM4—brain—acquired immunodeficiency syndrome	0.000851	0.0215	CbGeAlD
Brompheniramine—CHRM5—central nervous system—acquired immunodeficiency syndrome	0.000838	0.0212	CbGeAlD
Brompheniramine—CHRM5—brain—acquired immunodeficiency syndrome	0.000665	0.0168	CbGeAlD
Brompheniramine—CHRM3—digestive system—acquired immunodeficiency syndrome	0.000629	0.0159	CbGeAlD
Brompheniramine—CHRM2—nervous system—acquired immunodeficiency syndrome	0.000598	0.0151	CbGeAlD
Brompheniramine—CHRM1—lung—acquired immunodeficiency syndrome	0.000587	0.0149	CbGeAlD
Brompheniramine—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000585	0.0148	CbGeAlD
Brompheniramine—CHRM2—central nervous system—acquired immunodeficiency syndrome	0.000575	0.0146	CbGeAlD
Brompheniramine—CYP2B6—skin of body—acquired immunodeficiency syndrome	0.000573	0.0145	CbGeAlD
Brompheniramine—CYP2C19—blood—acquired immunodeficiency syndrome	0.000557	0.0141	CbGeAlD
Brompheniramine—CHRM1—nervous system—acquired immunodeficiency syndrome	0.000544	0.0138	CbGeAlD
Brompheniramine—KCNH2—blood—acquired immunodeficiency syndrome	0.000532	0.0134	CbGeAlD
Brompheniramine—CHRM1—central nervous system—acquired immunodeficiency syndrome	0.000524	0.0132	CbGeAlD
Brompheniramine—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000517	0.0131	CbGeAlD
Brompheniramine—KCNH2—bone marrow—acquired immunodeficiency syndrome	0.000514	0.013	CbGeAlD
Brompheniramine—KCNH2—spinal cord—acquired immunodeficiency syndrome	0.000512	0.013	CbGeAlD
Brompheniramine—KCNH2—vagina—acquired immunodeficiency syndrome	0.000493	0.0125	CbGeAlD
Brompheniramine—CHRM3—nervous system—acquired immunodeficiency syndrome	0.000487	0.0123	CbGeAlD
Brompheniramine—CYP2C8—blood—acquired immunodeficiency syndrome	0.000486	0.0123	CbGeAlD
Brompheniramine—CHRM3—central nervous system—acquired immunodeficiency syndrome	0.000469	0.0119	CbGeAlD
Brompheniramine—CYP2B6—lymphoid tissue—acquired immunodeficiency syndrome	0.000464	0.0117	CbGeAlD
Brompheniramine—CYP2B6—digestive system—acquired immunodeficiency syndrome	0.000458	0.0116	CbGeAlD
Brompheniramine—CHRM2—brain—acquired immunodeficiency syndrome	0.000457	0.0116	CbGeAlD
Brompheniramine—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000454	0.0115	CbGeAlD
Brompheniramine—CYP2C8—vagina—acquired immunodeficiency syndrome	0.000451	0.0114	CbGeAlD
Brompheniramine—HRH1—digestive system—acquired immunodeficiency syndrome	0.000447	0.0113	CbGeAlD
Brompheniramine—CYP2B6—blood—acquired immunodeficiency syndrome	0.000436	0.011	CbGeAlD
Brompheniramine—CYP2E1—lymphoid tissue—acquired immunodeficiency syndrome	0.000435	0.011	CbGeAlD
Brompheniramine—CYP2C9—blood—acquired immunodeficiency syndrome	0.000432	0.0109	CbGeAlD
Brompheniramine—KCNH2—nervous system—acquired immunodeficiency syndrome	0.000432	0.0109	CbGeAlD
Brompheniramine—CYP2E1—digestive system—acquired immunodeficiency syndrome	0.00043	0.0109	CbGeAlD
Brompheniramine—CHRM1—brain—acquired immunodeficiency syndrome	0.000416	0.0105	CbGeAlD
Brompheniramine—KCNH2—central nervous system—acquired immunodeficiency syndrome	0.000416	0.0105	CbGeAlD
Brompheniramine—CYP2E1—blood—acquired immunodeficiency syndrome	0.000409	0.0104	CbGeAlD
Brompheniramine—CYP2B6—vagina—acquired immunodeficiency syndrome	0.000404	0.0102	CbGeAlD
Brompheniramine—HRH1—vagina—acquired immunodeficiency syndrome	0.000395	0.00999	CbGeAlD
Brompheniramine—CYP2E1—spinal cord—acquired immunodeficiency syndrome	0.000395	0.00998	CbGeAlD
Brompheniramine—CYP2B6—lung—acquired immunodeficiency syndrome	0.000383	0.00967	CbGeAlD
Brompheniramine—HRH1—lung—acquired immunodeficiency syndrome	0.000374	0.00945	CbGeAlD
Brompheniramine—CHRM3—brain—acquired immunodeficiency syndrome	0.000372	0.00941	CbGeAlD
Brompheniramine—CYP2E1—lung—acquired immunodeficiency syndrome	0.000359	0.00908	CbGeAlD
Brompheniramine—CYP2B6—nervous system—acquired immunodeficiency syndrome	0.000354	0.00896	CbGeAlD
Brompheniramine—HRH1—nervous system—acquired immunodeficiency syndrome	0.000346	0.00875	CbGeAlD
Brompheniramine—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000346	0.00875	CbGeAlD
Brompheniramine—CYP2B6—central nervous system—acquired immunodeficiency syndrome	0.000341	0.00863	CbGeAlD
Brompheniramine—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.00034	0.00861	CbGeAlD
Brompheniramine—HRH1—central nervous system—acquired immunodeficiency syndrome	0.000333	0.00842	CbGeAlD
Brompheniramine—CYP2E1—nervous system—acquired immunodeficiency syndrome	0.000332	0.00841	CbGeAlD
Brompheniramine—KCNH2—brain—acquired immunodeficiency syndrome	0.00033	0.00834	CbGeAlD
Brompheniramine—CYP3A4—blood—acquired immunodeficiency syndrome	0.000329	0.00833	CbGeAlD
Brompheniramine—CYP2D6—blood—acquired immunodeficiency syndrome	0.000324	0.0082	CbGeAlD
Brompheniramine—CYP2E1—central nervous system—acquired immunodeficiency syndrome	0.00032	0.00809	CbGeAlD
Brompheniramine—KCNH2—lymph node—acquired immunodeficiency syndrome	0.000319	0.00806	CbGeAlD
Brompheniramine—CYP2C8—brain—acquired immunodeficiency syndrome	0.000302	0.00763	CbGeAlD
Brompheniramine—CYP2B6—brain—acquired immunodeficiency syndrome	0.000271	0.00685	CbGeAlD
Brompheniramine—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000267	0.00676	CbGeAlD
Brompheniramine—HRH1—brain—acquired immunodeficiency syndrome	0.000264	0.00669	CbGeAlD
Brompheniramine—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000263	0.00666	CbGeAlD
Brompheniramine—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000258	0.00651	CbGeAlD
Brompheniramine—HRH1—lymph node—acquired immunodeficiency syndrome	0.000255	0.00646	CbGeAlD
Brompheniramine—CYP2E1—brain—acquired immunodeficiency syndrome	0.000254	0.00643	CbGeAlD
Brompheniramine—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000253	0.00641	CbGeAlD
Brompheniramine—CYP2D6—brain—acquired immunodeficiency syndrome	0.000201	0.00509	CbGeAlD
Brompheniramine—CHRM5—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.66e-05	0.00238	CbGpPWpGaD
Brompheniramine—HRH1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	1.64e-05	0.00235	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	1.63e-05	0.00234	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	1.63e-05	0.00233	CbGpPWpGaD
Brompheniramine—HRH1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	1.62e-05	0.00232	CbGpPWpGaD
Brompheniramine—CHRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	1.61e-05	0.00231	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	1.61e-05	0.00231	CbGpPWpGaD
Brompheniramine—CHRM3—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	1.61e-05	0.0023	CbGpPWpGaD
Brompheniramine—CHRM2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	1.59e-05	0.00228	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.56e-05	0.00224	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—TAT—acquired immunodeficiency syndrome	1.55e-05	0.00223	CbGpPWpGaD
Brompheniramine—HRH1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	1.54e-05	0.00221	CbGpPWpGaD
Brompheniramine—HRH1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	1.54e-05	0.00221	CbGpPWpGaD
Brompheniramine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	1.54e-05	0.0022	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	1.54e-05	0.0022	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	1.54e-05	0.0022	CbGpPWpGaD
Brompheniramine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	1.53e-05	0.0022	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	1.53e-05	0.00219	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	1.53e-05	0.00219	CbGpPWpGaD
Brompheniramine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	1.53e-05	0.00219	CbGpPWpGaD
Brompheniramine—KCNH2—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	1.52e-05	0.00218	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	1.52e-05	0.00217	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	1.52e-05	0.00217	CbGpPWpGaD
Brompheniramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	1.51e-05	0.00217	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	1.5e-05	0.00216	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	1.5e-05	0.00215	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	1.49e-05	0.00214	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.49e-05	0.00214	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	1.48e-05	0.00212	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	1.47e-05	0.0021	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	1.46e-05	0.0021	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	1.46e-05	0.00209	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	1.44e-05	0.00207	CbGpPWpGaD
Brompheniramine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	1.39e-05	0.00199	CbGpPWpGaD
Brompheniramine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	1.38e-05	0.00198	CbGpPWpGaD
Brompheniramine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	1.38e-05	0.00197	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.37e-05	0.00197	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.37e-05	0.00196	CbGpPWpGaD
Brompheniramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	1.36e-05	0.00195	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.36e-05	0.00195	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.36e-05	0.00194	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.35e-05	0.00194	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.34e-05	0.00192	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—TAT—acquired immunodeficiency syndrome	1.34e-05	0.00192	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—AGPS—acquired immunodeficiency syndrome	1.32e-05	0.00189	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.32e-05	0.00189	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.31e-05	0.00188	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.31e-05	0.00188	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.31e-05	0.00188	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—TAT—acquired immunodeficiency syndrome	1.31e-05	0.00188	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.29e-05	0.00184	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.29e-05	0.00184	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.26e-05	0.0018	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.26e-05	0.0018	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.24e-05	0.00178	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.23e-05	0.00177	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.23e-05	0.00177	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.19e-05	0.00171	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.19e-05	0.0017	CbGpPWpGaD
Brompheniramine—HRH1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.17e-05	0.00168	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.17e-05	0.00167	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.17e-05	0.00167	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.17e-05	0.00167	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.16e-05	0.00167	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.15e-05	0.00165	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.14e-05	0.00163	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—AGPS—acquired immunodeficiency syndrome	1.14e-05	0.00163	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—TAT—acquired immunodeficiency syndrome	1.13e-05	0.00162	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.12e-05	0.0016	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.12e-05	0.0016	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.11e-05	0.0016	CbGpPWpGaD
Brompheniramine—HRH1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.06e-05	0.00151	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.05e-05	0.00151	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.05e-05	0.0015	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.04e-05	0.00149	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	1.01e-05	0.00145	CbGpPWpGaD
Brompheniramine—CHRM2—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	1e-05	0.00144	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	9.79e-06	0.0014	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	9.64e-06	0.00138	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—AGPS—acquired immunodeficiency syndrome	9.62e-06	0.00138	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	9.37e-06	0.00134	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	9.3e-06	0.00133	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	9.29e-06	0.00133	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	9.27e-06	0.00133	CbGpPWpGaD
Brompheniramine—HRH1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	9.26e-06	0.00133	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	9.24e-06	0.00132	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	9.23e-06	0.00132	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	9.23e-06	0.00132	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	9.21e-06	0.00132	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	9.2e-06	0.00132	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	9.15e-06	0.00131	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	9.11e-06	0.00131	CbGpPWpGaD
Brompheniramine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	9e-06	0.00129	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	8.89e-06	0.00127	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	8.89e-06	0.00127	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	8.89e-06	0.00127	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	8.86e-06	0.00127	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	8.86e-06	0.00127	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	8.83e-06	0.00127	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	8.83e-06	0.00127	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	8.82e-06	0.00126	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	8.76e-06	0.00125	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	8.75e-06	0.00125	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	8.75e-06	0.00125	CbGpPWpGaD
Brompheniramine—HRH1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	8.7e-06	0.00125	CbGpPWpGaD
Brompheniramine—HRH1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	8.7e-06	0.00125	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	8.68e-06	0.00124	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	8.68e-06	0.00124	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	8.65e-06	0.00124	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	8.65e-06	0.00124	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	8.59e-06	0.00123	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	8.56e-06	0.00123	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	8.56e-06	0.00123	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	8.51e-06	0.00122	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	8.44e-06	0.00121	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	8.41e-06	0.0012	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	8.38e-06	0.0012	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	8.38e-06	0.0012	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	8.35e-06	0.0012	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	8.27e-06	0.00119	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	8.12e-06	0.00116	CbGpPWpGaD
Brompheniramine—CHRM2—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	8.09e-06	0.00116	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	8.04e-06	0.00115	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	8.01e-06	0.00115	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	8.01e-06	0.00115	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	7.99e-06	0.00114	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	7.91e-06	0.00113	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	7.9e-06	0.00113	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	7.9e-06	0.00113	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	7.9e-06	0.00113	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	7.88e-06	0.00113	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	7.88e-06	0.00113	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	7.85e-06	0.00113	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	7.85e-06	0.00113	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	7.83e-06	0.00112	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	7.78e-06	0.00111	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	7.78e-06	0.00111	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	7.77e-06	0.00111	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	7.67e-06	0.0011	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.34e-06	0.00105	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.03e-06	0.00101	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.9e-06	0.000989	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.9e-06	0.000989	CbGpPWpGaD
Brompheniramine—CHRM1—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	6.69e-06	0.000958	CbGpPWpGaD
Brompheniramine—HRH1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.62e-06	0.000949	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.61e-06	0.000947	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.61e-06	0.000947	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.6e-06	0.000946	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.58e-06	0.000943	CbGpPWpGaD
Brompheniramine—HRH1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	6.52e-06	0.000935	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.52e-06	0.000934	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	6.5e-06	0.000932	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	6.48e-06	0.000929	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	6.42e-06	0.00092	CbGpPWpGaD
Brompheniramine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	6.36e-06	0.000911	CbGpPWpGaD
Brompheniramine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	6.34e-06	0.000908	CbGpPWpGaD
Brompheniramine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	6.32e-06	0.000905	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	6.07e-06	0.00087	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.01e-06	0.000862	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	5.99e-06	0.000859	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	5.97e-06	0.000856	CbGpPWpGaD
Brompheniramine—HRH1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	5.97e-06	0.000855	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	5.95e-06	0.000852	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	5.93e-06	0.000849	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5.92e-06	0.000849	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	5.92e-06	0.000848	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5.9e-06	0.000846	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5.88e-06	0.000843	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	5.87e-06	0.000841	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5.83e-06	0.000835	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.49e-06	0.000787	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.47e-06	0.000784	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.46e-06	0.000782	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.42e-06	0.000776	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.4e-06	0.000774	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.4e-06	0.000774	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.38e-06	0.000771	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.33e-06	0.000764	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.25e-06	0.000752	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.17e-06	0.000741	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	5.16e-06	0.00074	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.1e-06	0.00073	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.03e-06	0.000721	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.97e-06	0.000712	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.95e-06	0.00071	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.95e-06	0.000709	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.93e-06	0.000707	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.89e-06	0.0007	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.88e-06	0.000699	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.73e-06	0.000678	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.67e-06	0.000669	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.67e-06	0.000669	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.65e-06	0.000667	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.65e-06	0.000667	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.64e-06	0.000665	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.64e-06	0.000665	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.63e-06	0.000663	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.59e-06	0.000658	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.59e-06	0.000658	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.53e-06	0.000649	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	4.43e-06	0.000635	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.43e-06	0.000635	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	3.96e-06	0.000567	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	3.61e-06	0.000517	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.55e-06	0.000509	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.54e-06	0.000507	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.53e-06	0.000506	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.5e-06	0.000501	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.5e-06	0.000501	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.49e-06	0.0005	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.48e-06	0.000498	CbGpPWpGaD
Brompheniramine—HRH1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.45e-06	0.000494	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.44e-06	0.000493	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.44e-06	0.000492	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.42e-06	0.000491	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.39e-06	0.000486	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.2e-06	0.000459	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.19e-06	0.000457	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.18e-06	0.000456	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.15e-06	0.000451	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.13e-06	0.000448	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.12e-06	0.000447	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.11e-06	0.000446	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.08e-06	0.000441	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.73e-06	0.000392	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.72e-06	0.00039	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—ALB—acquired immunodeficiency syndrome	2.71e-06	0.000388	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.62e-06	0.000375	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.6e-06	0.000373	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—ALB—acquired immunodeficiency syndrome	2.33e-06	0.000334	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—ALB—acquired immunodeficiency syndrome	2.28e-06	0.000327	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—ALB—acquired immunodeficiency syndrome	1.97e-06	0.000283	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.85e-06	0.000265	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.84e-06	0.000264	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.84e-06	0.000264	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.84e-06	0.000263	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.83e-06	0.000263	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.83e-06	0.000262	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.82e-06	0.000261	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.81e-06	0.000259	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	1.76e-06	0.000252	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	1.62e-06	0.000232	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.61e-06	0.00023	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	1.61e-06	0.00023	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.54e-06	0.00022	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.09e-06	0.000156	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.08e-06	0.000155	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.08e-06	0.000155	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.07e-06	0.000153	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	1.06e-06	0.000152	CbGpPWpGaD
